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ABSTRACT: Absolute quantiﬁcation of proteins in tissue is important for numerous ﬁelds of study. Liquid chromatography−
mass spectrometry (LC−MS) methods are the norm but typically involve lengthy sample preparation including tissue
homogenization, which results in the loss of information relating to spatial distribution. Here, we propose liquid extraction
surface analysis (LESA) mass spectrometry (MS) of stable isotope labeled mimetic tissue models for the spatially resolved
quantiﬁcation of intact ubiquitin in rat and mouse brain tissue. Measured ubiquitin concentrations are in agreement with values
found in the literature. Images of rat and mouse brain tissue demonstrate spatial variation in the concentration of ubiquitin and
demonstrate the utility of spatially resolved quantitative measurement of proteins in tissue. Although we have focused on
ubiquitin, the method has the potential for broader application to the absolute quantitation of any endogenous protein or
protein-based drug in tissue.
Proteins are important molecules that play key roles in alllife processes. Many proteins serve as biomarkers which
distinguish between healthy and diseased tissues; therefore,
their quantiﬁcation may potentially reveal new information
about disease state. Relative quantiﬁcation can be achieved by
comparing the abundance of protein signals in diﬀerent
physiological states. Absolute quantiﬁcation requires compar-
ison to the ion abundance detected from samples of known
composition. Liquid chromatography coupled to mass
spectrometry (LC−MS) is commonly employed in the
quantiﬁcation of proteins in biological samples. Usually this
involves a bottom-up approach in which the protein is digested
into proteolytic peptides and tagging of the protein (or its
peptides) with a label containing stable isotope(s). The label
may be introduced via metabolic, chemical, or enzymatic
means.1,2 Commonly used methods include stable isotope
labeling by amino acid in cell culture (SILAC), isotope-coded
aﬃnity tags (ICAT), isobaric tags for relative and absolute
quantiﬁcation (iTRAQ), and dimethyl labeling.1−3 Sample
preparation for such methods is lengthy and there are inherent
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challenges associated with bottom-up protein identiﬁcation
such as ineﬃcient digestion, failure to identify peptides, and
loss of post-translational modiﬁcations.4 The alternative to
proteolytic digestion is the top-down approach in which intact
proteins are analyzed by tandem mass spectrometry.5 Top-
down quantiﬁcation approaches use both labeling and label-
free methods; however, labeling has been shown to have its
limitations and label-free methods require robust tools for data
analysis.6 Top-down protein quantiﬁcation involves LC−MS
separation prior to MS analysis, and LC−MS typically requires
sample homogenization. Consequently, spatial information is
not retained meaning valuable biological information is lost.7,8
Mass spectrometry imaging (MSI) enables spatial proﬁling
of analytes within thin tissue sections. Ambient MSI methods
are particularly suited to quantitative analysis, due to the
limited sample preparation required.9 Samples do not undergo
any speciﬁc sample preparation, such as addition of a matrix
compound, resulting in lower ion suppression and enhanced
sensitivity.10 A number of examples of quantitative ambient
MSI have been reported.11−13 Liquid sampling techniques in
which desorption and ionization stages are decoupled are even
more attractive because this aﬀords the opportunity for oﬀ-line
incorporation of an internal standard.14
In 2013, Groseclose and Castellino reported a novel method
for spatially resolved quantiﬁcation of small molecule drugs in
tissue via matrix-assisted laser desorption ionization (MALDI)
MS imaging (MSI),7 which has since been adopted in
conjunction with MALDI and other mass spectrometry
imaging techniques.8,12−15 The production of an external
calibration sample comprised of tissue homogenates spiked
with known amounts of isotopically labeled analyte of interest,
termed the “mimetic tissue model”, enabled absolute
quantitation. Thin tissue sections of the mimetic model were
placed adjacent to sections from experimental samples and
imaged under the same conditions. A calibration curve was
generated from the mimetic model, and the experimental
sample compared against this. Groseclose and Castellino
demonstrated that the histology (overall tissue density and
distribution of cell nuclei) and mass spectra (total ion
currents) were consistent between the mimetic model and
intact tissues, i.e., the homogenized and nonhomogenized
tissue are comparable as background matrixes. A study by
Swales et al. reported quantitative LESA imaging of four drug
compounds in rat liver using the mimetic tissue model
approach.14
Herein we demonstrate the use of LESA MS for the
quantiﬁcation of intact proteins in biological tissue using the
example of ubiquitin. Ubiquitin is a regulatory protein involved
in many processes, most notably protein degradation. It is
found in every cell type, and it is highly conserved through
eukaryotic species.16 It is therefore a suitable model for the
quantitative LESA MS approach. In this study, we have
incorporated stable isotope labeled (C13, N15) ubiquitin into a
rat brain tissue mimetic model for use as a calibration reference
standard. We were able to perform quantitative imaging via
stable isotope labeled mimetics (SLiM) LESA MS of ubiquitin
in rat and mouse brain tissue with a pixel size of 2 mm.
Calculated concentration values of ubiquitin across the tissue
were compared to those reported in the literature measured via
LC−MS techniques and were found to be in good agreement.
Figure 1. (A) Rat brain tissue mimetic section mounted on a glass slide with LESA sampling points indicated. (B) Mass spectra of the rat brain
tissue mimetic models. Top, 163 nmol/g of labeled ubiquitin; middle, 68.6 nmol/g of labeled ubiquitin; bottom, blank mimetic. (C) Ion intensity
image comparison of labeled ubiquitin in charge states 9+, m/z 1005.1788 and 10+, m/z 904.7624 in tissue mimetic models. Each horizontal line
represents one mimetic concentration in nmol/g. (D) Calibration curve for the 9+ charge state of labeled ubiquitin. Calibration data points are
shown in black; validation data points are shown in blue. Least squares ﬁtting was applied to the calibration data.
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In developing this method, we followed the FDA guidelines
for Bioanalytical Method Validation.17 Validation parameters
include lower limit of quantiﬁcation (LLOQ), upper limit of
quantiﬁcation (ULOQ), precision (represented by coeﬃcient
of variation), accuracy (% diﬀerence between experimental and
nominal values), selectivity, sensitivity, reproducibility, and
stability of samples over time.
■ RESULTS AND DISCUSSION
A method was devised to measure the concentration of
ubiquitin in rat and mouse brain tissue in a spatially resolved
manner. The workﬂow is summarized in Figure S1 (see the
Supporting Information); brieﬂy, a mimetic tissue model was
prepared by spiking known quantities of C13, N15-labeled
ubiquitin into homogenized rat brain tissue. The labeled
ubiquitin is chemically identical to endogenous ubiquitin and is
therefore assumed to have the same solubility and desorption/
ionization eﬃciency. The isotopic labeling of ubiquitin with
C13 and N15 results in a mass shift of 473.8612 Da between the
labeled (9033.4779 Da) and endogenous (8559.6167 Da)
proteins, allowing the labeled protein to be detected without
interference from the endogenous ubiquitin (which is present
in all brain tissues). Thin tissue sections of the mimetic tissue
model were placed adjacent to sections of rat or mouse brain
tissue on a glass slide, and the whole slide was imaged using
LESA MSI. An example section of the tissue mimetic model,
labeled with LESA sampling locations, is presented in Figure
1A. Example mass spectra from three mimetics with diﬀerent
concentrations (Figure 1B) show that it was possible to detect
both endogenous and labeled ubiquitin simultaneously. Both
endogenous and labeled ubiquitin were observed in 7+
through 10+ charge states, with the most abundant charge
states being 9+ and 10+. The relative abundance of the labeled
ubiquitin increases with mimetic concentration (and none is
observed in the blank), whereas the relative abundance of the
endogenous ubiquitin remains constant. Figure 1C represents
overview intensity maps of the 9+ and 10+ charge states of
labeled ubiquitin following LESA MS of the mimetics. Each
row comprises eight separate sampling locations for a speciﬁc
labeled ubiquitin concentration (i.e., one row per mimetic
concentration).
A total of seven mimetics with nonzero concentrations were
prepared and analyzed. In the initial experiment, the most
abundant charge state observed in the mass spectra was 10+.
Therefore, the signal intensity of the most abundant
isotopomer of the 10+ charge state was plotted against the
mimetic ubiquitin concentration (see Figure S2). FDA
guidance for the validation of analytical and bioanalytical
methods17 states that the analyte response at the lower limit of
quantiﬁcation (LLOQ) should be at least 5 times that of the
blank response. Results for the three lowest concentration
mimetics did not meet this criterion, where the LLOQ was
68.6 nmol/g, and were excluded from the data set. The upper
limit of quantiﬁcation (ULOQ) for these experiments was 163
nmol/g (% CV 7.55%).
Subsequent experiments made use of ﬁve mimetic
concentrations (blank, 68.6 nmol/g, 94.7 nmol/g, 122.6
nmol/g, 163 nmol/g). For each concentration, seven locations
were sampled. Replicate data acquired for each calibration
sample were randomly split into 4 calibration and 3 validation
(or quality control) data points in accordance with FDA
guidance.17 In these experiments, the most abundant charge
state was observed to be 9+ instead of 10+, and therefore the
calibration data points were used to generate a calibration
curve from the 9+ charge state (see Figure 1D). The data were
analyzed by linear regression and a line was ﬁtted with an
associated R of 0.948 (R2 = 0.898). Individual data points
acquired from the same concentration sample showed a fairly
high level of variation (see Figure 1C,D). Variation can be
introduced during LESA sampling and analysis via several
routes including variable spreading of the sampling droplet
resulting in variation in area sampled, variation in proportion
of sampling solvent recovered from the surface during
reaspiration, and in the case of sampling a tissue mimetic,
spatial variation in concentration resulting from incomplete
mixing of the homogenate. An assessment of homogenate
mixing was performed by taking multiple sections at various
depths of the mimetic volume, see Figure S3. The level of
variability in the labeled and endogenous protein signal was
comparable; therefore, the source of variation is more likely a
function of the sampling process. The incorporation of an
internal standard (at ﬁxed concentration) into the sampling
solvent or coated as a homogeneous layer over the sample
could address this challenge; however, a second labeled version
of the protein would be required for each separate internal
standard, considerably increasing the cost of the experiment.
This will be considered as a future step toward improving the
reproducibility of the method.
The three validation data points (at each of the mimetic
concentrations) were used to provide assessment of the
method according to the guidance provided by the FDA for
the validation of analytical and bioanalytical methods.17 The
mean experimental concentration was calculated and com-
pared with the nominal concentration of the mimetic (see
Table 1). The coeﬃcient of variation (% CV) between the
experimental concentration and the nominal concentration of
each mimetic sample was then calculated and meets the FDA
precision requirements (<15%, and <20% for the LLOQ) for
all mimetic samples. To measure the accuracy of the method,
the % diﬀerence between back-calculated and nominal
concentrations were calculated. To meet accuracy require-
ments, concentrations must fall within 15% deviation of the
mean, except for LLOQ where 20% deviation is acceptable.
Two of the three samples meet this requirement.
To demonstrate the selectivity of our method, we calculated
the mean concentration in the blank mimetic sample which
was 1.3 nmol/g and below our LLOQ. Sensitivity is deﬁned as
the LLOQ as long as it fulﬁlls the accuracy and precision
requirements; therefore, the sensitivity of the method is 68.6
nmol/g.
Table 1. Nominal and Calculated Concentration of Validation/Quality Control (QC) Data Points with Standard Deviation,
Coeﬃcient of Variation (% CV), and Calculated % Diﬀerence
QC sample nominal concentration [nmol/g] mean of the calculated concentration [nmol/g] standard deviation % CV % diﬀerence
high QC 163.0 150.68 16.66 11.09 7.55
middle QC 122.6 162.32 7.29 4.49 32.40
low QC 68.6 67.01 11.78 17.58 2.32
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Sagittal sections of rat and mouse brain (ubiquitin is highly
conserved through eukaryotic species, i.e., the protein
sequence is the same in both organisms) were imaged using
LESA MS under the same sampling parameters as the
calibration samples to quantify endogenous ubiquitin, see
Figure S4. The average concentration of ubiquitin detected
across the whole rat brain section was 139.641 ± 95.403 nmol/
g and in mouse brain was 90.233 ± 51.512 nmol/g. Assuming
an average rat brain mass of 2 g and mouse brain of 0.4 g,18
these values equate to ∼2.392 ±1.634 mg ubiquitin per rat
brain and ∼0.309 ± 0.177 mg per mouse brain. Kaiser et al.
used a protein standard absolute quantiﬁcation (PSAQ)
method which uses LC−MS to quantify ubiquitin in mouse
brain tissue and found that the total concentration of ubiquitin
was ∼121 nmol/g tissue.16 This equates to ∼0.416 (±0.017)
mg ubiquitin per brain. To date and to our knowledge, there is
no information about the total ubiquitin content in the rat
brain available; therefore, it was not possible to compare the
calculated results to any reference value. Considering the size
of the rat and mouse brain, these numbers are in approximate
agreement. The LESA images in Figure S4 also suggest there
might be a variability in the ubiquitin distribution across the
brain. The mouse tissue shows higher variability compared to
the rat tissue.
A complete repeat of the same experiment was performed 1
year after the initial experiment (see Figure S5), using the same
mimetic samples and quantifying ubiquitin in the rat brain by
using the most abundant charge state in those experiments
(10+). The average concentration of ubiquitin in the rat brain
was measured at 129.358 ± 98.401 nmol/g corresponding to
∼2.216 ± 1.686 mg of ubiquitin per rat brain. The percentage
diﬀerence between this value and the value from the repeated
experiment is within 7.4%. FDA guidelines suggest that the
variation ±15% is acceptable, and therefore this result
demonstrates the stability of the samples and reproducibility
of the method.
■ CONCLUSIONS
We report quantitative mass spectrometry imaging of ubiquitin
in tissue for the ﬁrst time. The method passes validation
criteria for LLOQ, ULOQ, selectivity, sensitivity, precision,
reproducibility, and stability according to FDA guidelines.
Absolute quantiﬁcation of ubiquitin was performed in a pixel-
wise fashion and demonstrated variability of ubiquitin
concentration in diﬀerent regions of the mouse and rat
brain. Results obtained from the two most abundant charge
states 9+ and 10+ were in good agreement. Future work will
focus on incorporation of an internal standard into the
workﬂow to improve the variability related to extraction
eﬃciency, accuracy, and signal intensity observed in LESA
sampling. Although the focus here was on ubiquitin, the
method could in principle be adapted, with appropriate
validation, to measure the absolute concentration of any
protein in tissue including endogenous proteins and antibodies
or protein-based therapeutic compounds.
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